X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will used in the development of CLR 131 (iopofosine I-131), designed to provide targeted delivery of iodine-131 directly to cancer cells. It is being evaluated in patients with Waldenstrom Macroglobulinemia, Multiple Myeloma, and Chronic Lymphocytic Leukemia.
Lead Product(s): Iopofosine I-131
Therapeutic Area: Oncology Product Name: CLR 131
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Rosalind Advisors
Deal Size: $44.1 million Upfront Cash: Undisclosed
Deal Type: Private Placement January 25, 2024
Details:
CLR 121225 (225Ac-CLR-121225) is an actinium-labeled phospholipid ether. It is a novel α-emitting phospholipid radiotherapeutic conjugate. It is being evaluated in IND-enabling studies for refractory pancreatic cancer.
Lead Product(s): 225Ac-CLR 121225
Therapeutic Area: Oncology Product Name: CLR 121225
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2024
Details:
The partnership aims to advance the treatment of Waldenstrom's macroglobulinemia with Cellectar’s iopofosine I 131, a novel phospholipid radiotherapeutic conjugate.
Lead Product(s): Iopofosine I-131
Therapeutic Area: Oncology Product Name: CLR 131
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Meaningful Insights-BioTech Analytics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 11, 2024
Details:
CLR 131 (Iopofosine I 131) is a potential first-in-class, targeted radiotherapy candidate, which is under phase 2 clinical development for the treatment of relapsed/refractory Waldenstrom’s macroglobulinemia.
Lead Product(s): Iopofosine I-131
Therapeutic Area: Oncology Product Name: CLR 131
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Details:
I-131-CLR1404 (Iopofosine I 131) is a small-molecule Phospholipid Drug Conjugate™ designed to provide targeted delivery of iodine-131 (radioisotope) directly to cancer cells, while limiting exposure to healthy cells.
Lead Product(s): Iopofosine I 131
Therapeutic Area: Oncology Product Name: I-131-CLR1404
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2022
Details:
The grant will be used to support and accelerate the ongoing pivotal study of iopofosine I-131 (CLR 131) in Waldenstrom’s macroglobulinemia (WM) patients who have received at least two prior lines of therapy.
Lead Product(s): Iopofosine I-131
Therapeutic Area: Oncology Product Name: CLR-131
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Cancer Institute
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Funding August 18, 2021
Details:
The agreement with Evergreen provides long term commercial supply of iopofosine I-131 and supply of clinical study material for Cellectar’s pivotal study in Waldenstrom’s macroglobulinemia (WM) as well as ongoing Phase 1 and Phase 2 clinical studies.
Lead Product(s): Iopofosine I-131
Therapeutic Area: Oncology Product Name: CLR-131
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Evergreen Theragnostics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 16, 2021
Details:
The collaboration focuses on combining IntoCell’s validated novel Ortho-Hydroxy Protected Aryl Sulfate (OHPAS) linker chemistry with Cellectar’s validated novel targeting platform, phospholipid ethers (PLEs) to develop new PDCs.
Lead Product(s): Phospholipid Drug Conjugates
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Recipient: IntoCell
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration July 13, 2021
Details:
Cellectar is conducting pivotal trial evaluating CLR 131 in Waldenstrom’s macroglobulinemia patients that have failed or had a suboptimal response to a Bruton’s tyrosine kinase inhibitor in U.S and intends to expand the trial to additional US and international sites.
Lead Product(s): CLR 131
Therapeutic Area: Oncology Product Name: I-131-CLR1404
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 27, 2021
Details:
Patent covers the phospholipid ether (PLE) delivery vehicle combined with I-131 and I-125.
Lead Product(s): CLR 131
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 14, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
